| Biomarker ID | 1035 |
| PMID | 23308129 |
| Year | 2013 |
| Biomarker | BMI1 |
| Biomarker Basis | Concentration Based (ng/mL) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated with Advanced Stage PCa (stage 2: 3.91±.60 Vs Stage 3: 8.55 ±1.95; Stage 4: 10.84 ± 2.44) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: PRC2 complex long-term gene silencing through modification of histone tails, Myc active pathway, Senescence and autophagy, T cell receptor regulation of apoptosis |
| Experiment | Stage 2 Vs Stage 3 Vs Stage 4 Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | 58 human subjects representing normal disease free condition, and different CaP stages, viz., normal (n = 10), Stage II CaP (n=16), Stage III CaP (n=15), and Stage IV CaP (n=17). |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p< 0.001 |
| Method Used | Immunohistochemistry; ELISA, western-blot |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |